BBOT

BridgeBio Oncology Therapeutics, Inc. BBOT

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$3.55M

Quarter to Jun 30

Net income

$-56.45M

Quarter to Jun 30

Free cash flow

$-44.41M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$450.59M total
Cormorant Asset Management, LP
$136.23M0.0%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$37.23M0.0%
Omega Fund Management, LLC
$25.07M0.0%
EcoR1 Capital, LLC
$21.51M0.0%
Alphabet Inc.
$21.51M0.0%
WELLINGTON MANAGEMENT GROUP LLP
$21.25M-1.0%
Enavate Sciences GP, LLC
$20.02M0.0%
CITADEL ADVISORS LLC
$19.95M+3.5%
Novo Holdings A/S
$17.14M+2.9%
BlackRock, Inc.
$16.41M+3.1%
VANGUARD CAPITAL MANAGEMENT LLC
$15.28M+272.5%
Laurion Capital Management LP
$15.26M+4.2%
ARMISTICE CAPITAL, LLC
$13.44M+32.8%
STATE STREET CORP
$7.90M+358.1%
Aisling Capital Management LP
$7.76M0.0%
Opaleye Management Inc.
$5.33M+1213.8%
GEODE CAPITAL MANAGEMENT, LLC
$4.74M+7.4%
Granahan Investment Management, LLC
$4.26M+141.7%
SPHERA FUNDS MANAGEMENT LTD.
$3.51MNew
ADAGE CAPITAL PARTNERS GP, L.L.C.
$3.05M0.0%
ROYCE & ASSOCIATES LP
$2.93M-39.5%
Catalio Capital Management, LP
$2.43MNew
PRICE T ROWE ASSOCIATES INC /MD/
$2.29M-31.5%
VANGUARD FIDUCIARY TRUST CO
$2.22M+14.6%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$2.18M-1.5%
See all 66 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q2 2026
EDGAR

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BBOT

Earnings Per Share

13fpro.ai/company/BBOT

Loading ratio trend…

BBOT key financials by period

Reported revenue, net income and operating margin by fiscal year, from BridgeBio Oncology Therapeutics, Inc.'s annual filings on SEC EDGAR.

BridgeBio Oncology Therapeutics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$11.3M$-134.0M—
FY 2024$6.4M$-74.3M—
Source: BBOT filings on SEC EDGAR →

BBOT insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About BridgeBio Oncology Therapeutics, Inc. (BBOT): stock profile, AI score and financials

BridgeBio Oncology Therapeutics, Inc. (BBOT) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BBOT is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), BridgeBio Oncology Therapeutics, Inc. reports quarterly revenue of $3.6M, net income of $-56.5M, free cash flow of $-44.4M. Top institutional holders of BBOT by reported 13-F value include Cormorant Asset Management, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Omega Fund Management, based on the most recent SEC filings. BBOT trades on the Nasdaq exchange and files with the SEC under CIK 1869105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BBOT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BridgeBio Oncology Therapeutics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1869105 →